SGLT2 Inhibitor (Type 2 Diabetes)Conditionally Approved

Dapagliflozin

Brand names: Farxiga|Last verified: 2026-03-01

FAA Pathway: Special Issuance (Diabetes Protocol)

Dapagliflozin is an SGLT2 inhibitor that may be approved through the FAA diabetes Special Issuance process. Standard diabetes pathway requirements apply — stable glucose, A1C monitoring, and no DKA episodes.

Check your medications

Look up any medication in our FAA compatibility database.

Medication Checker

Pilot Tip

Always report all medications on your FAA medical application (Form 8500-8, Item 17a), even OTC medications. Failure to disclose is a far bigger issue than the medication itself.

Certification Details

Key Requirements
A1C controlled, no DKA episodes
Certificate Classes
1st, 2nd, and 3rd class eligible
Monitoring
Quarterly A1C, renal function tests
Notes
Report on Form 8500-8 with diabetes documentation

Sources

  • FAA AME Guide — Pharmaceuticals: Diabetes Type II (faa.gov/ame_guide/pharm/oral_diabetes)

Last verified: 2026-03-01

Frequently Asked Questions

Is Dapagliflozin allowed for pilots?

The FAA considers Dapagliflozin (Farxiga) to be "Conditionally Approved" for medical certification purposes. Dapagliflozin is an SGLT2 inhibitor that may be approved through the FAA diabetes Special Issuance process. Standard diabetes pathway requirements apply — stable glucose, A1C monitoring, and no DKA episodes.

What is the FAA status of Dapagliflozin?

Dapagliflozin has a status of "Conditionally Approved" under FAA medical certification policy. The certification pathway is: Special Issuance (Diabetes Protocol).

Can I fly while taking Dapagliflozin?

Flying while taking Dapagliflozin may be possible through the FAA's Special Issuance process. You will need to meet specific requirements and obtain approval before exercising pilot privileges. Consult an experienced AME for guidance.

Important Notice

The FAA does not publish a comprehensive list of “approved” medications. The information on this page represents our interpretation of publicly available FAA guidance and is provided for informational and educational purposes only. It does not constitute medical advice, legal advice, or a guarantee of certification outcome.

The primary issue with the FAA is always whether the underlying medical condition — not just the medication — is compatible with safe flight. You should only start, stop, or change medications after consulting your treating physician. Always consult with a qualified Aviation Medical Examiner (AME) for guidance specific to your situation. FAA policies are subject to change. ClearedMed is not affiliated with or endorsed by the FAA.